Suppr超能文献

腹膜平衡试验与患者预后。

Peritoneal Equilibration Test and Patient Outcomes.

作者信息

Mehrotra Rajnish, Ravel Vanessa, Streja Elani, Kuttykrishnan Sooraj, Adams Scott V, Katz Ronit, Molnar Miklos Z, Kalantar-Zadeh Kamyar

机构信息

Kidney Research Institute, University of Washington, Seattle, Washington;

Department of Medicine, University of California, Irvine, Orange, California; and.

出版信息

Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1990-2001. doi: 10.2215/CJN.03470315. Epub 2015 Oct 13.

Abstract

BACKGROUND AND OBJECTIVES

Although a peritoneal equilibration test yields data on three parameters (4-hour dialysate/plasma creatinine, 4- to 0-hour dialysate glucose, and 4-hour ultrafiltration volume), all studies have focused on the prognostic value of dialysate/plasma creatinine for patients undergoing peritoneal dialysis. Because dialysate 4- to 0-hour glucose and ultrafiltration volume may be superior in predicting daily ultrafiltration, the likely mechanism for the association of peritoneal equilibration test results with outcomes, we hypothesized that they are superior to dialysate/plasma creatinine for risk prediction.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined unadjusted and adjusted associations of three peritoneal equilibration test parameters with all-cause mortality, technique failure, and hospitalization rate in 10,142 patients on peritoneal dialysis treated between January 1, 2007 and December 31, 2011 in 764 dialysis facilities operated by a single large dialysis organization in the United States, with a median follow-up period of 15.8 months; 87% were treated with automated peritoneal dialysis.

RESULTS

Demographic and clinical parameters explained only 8% of the variability in dialysate/plasma creatinine. There was a linear association between dialysate/plasma creatinine and mortality (adjusted hazards ratio per 0.1 unit higher, 1.07; 95% confidence interval, 1.02 to 1.13) and hospitalization rate (adjusted incidence rate ratio per 0.1 unit higher, 1.05; 95% confidence interval, 1.03 to 1.06). Dialysate/plasma creatinine and dialysate glucose were highly correlated (r=-0.84) and yielded similar risk prediction. Ultrafiltration volume was inversely related with hospitalization rate but not with all-cause mortality. None of the parameters were associated with technique failure. Adding 4- to 0-hour dialysate glucose, ultrafiltration volume, or both did not result in any improvement in risk prediction with dialysate/plasma creatinine alone.

CONCLUSIONS

This analysis from a large contemporary cohort treated primarily with automated peritoneal dialysis validates dialysate/plasma creatinine as a robust predictor of outcomes in patients treated with peritoneal dialysis.

摘要

背景与目的

尽管腹膜平衡试验可得出三个参数的数据(4小时透析液/血浆肌酐、4至0小时透析液葡萄糖以及4小时超滤量),但所有研究都聚焦于透析液/血浆肌酐对接受腹膜透析患者的预后价值。由于4至0小时透析液葡萄糖和超滤量在预测每日超滤方面可能更具优势,这可能是腹膜平衡试验结果与预后相关的机制,我们推测它们在风险预测方面优于透析液/血浆肌酐。

设计、地点、参与者及测量方法:我们研究了2007年1月1日至2011年12月31日期间在美国由一个大型透析组织运营的764个透析机构中接受腹膜透析的10142例患者,三个腹膜平衡试验参数与全因死亡率、技术失败率和住院率之间的未调整及调整后的关联;中位随访期为15.8个月;87%的患者接受自动腹膜透析治疗。

结果

人口统计学和临床参数仅解释了透析液/血浆肌酐变异性的8%。透析液/血浆肌酐与死亡率(每升高0.1单位的调整后风险比为1.07;95%置信区间为1.02至1.13)和住院率(每升高0.1单位的调整后发病率比为1.05;95%置信区间为1.03至1.06)之间存在线性关联。透析液/血浆肌酐与透析液葡萄糖高度相关(r = -0.84),且产生相似的风险预测。超滤量与住院率呈负相关,但与全因死亡率无关。这些参数均与技术失败无关。单独使用透析液/血浆肌酐时,加入4至0小时透析液葡萄糖、超滤量或两者均未使风险预测有任何改善。

结论

这项来自主要接受自动腹膜透析治疗的大型当代队列的分析证实,透析液/血浆肌酐是腹膜透析患者预后的可靠预测指标。

相似文献

1
Peritoneal Equilibration Test and Patient Outcomes.
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1990-2001. doi: 10.2215/CJN.03470315. Epub 2015 Oct 13.

引用本文的文献

1
Text mining for case report articles on "peritoneal dialysis" from PubMed database.
Ther Apher Dial. 2025 Jun;29(3):459-470. doi: 10.1111/1744-9987.70013. Epub 2025 Mar 26.
2
Resistant and Apparently Resistant Hypertension in Peritoneally Dialyzed Patients.
J Clin Med. 2025 Jan 2;14(1):218. doi: 10.3390/jcm14010218.
5
PET Testing Has Utility in the Prescription of Peritoneal Dialysis: Commentary.
Kidney360. 2024 Dec 1;5(12):1797-1798. doi: 10.34067/KID.0000000000000409. Epub 2024 Apr 4.
6
PET Testing Has Utility in the Prescription of Peritoneal Dialysis: PRO.
Kidney360. 2024 Dec 1;5(12):1791-1793. doi: 10.34067/KID.0000000000000434. Epub 2024 Apr 4.
8
Predicting solute transfer rate in patients initiating peritoneal dialysis.
J Nephrol. 2024 May;37(4):973-982. doi: 10.1007/s40620-023-01862-y. Epub 2024 Jan 30.
10
An update on absolute and relative indications for dialysis treatment modalities.
Clin Kidney J. 2023 Sep 13;16(Suppl 1):i39-i47. doi: 10.1093/ckj/sfad062. eCollection 2023 Sep.

本文引用的文献

2
Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.
J Am Soc Nephrol. 2013 Dec;24(12):2071-80. doi: 10.1681/ASN.2013030314. Epub 2013 Sep 5.
4
Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy.
Kidney Int Suppl. 2006 Nov(103):S76-83. doi: 10.1038/sj.ki.5001920.
5
Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis.
J Am Soc Nephrol. 2006 Sep;17(9):2591-8. doi: 10.1681/ASN.2006030194. Epub 2006 Aug 2.
7
Overfill or ultrafiltration? We need to be clear.
Perit Dial Int. 2006 Jul-Aug;26(4):449-51.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验